AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
4 Week, Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease
Phase 2
Completed
- Conditions
- Mild to Moderate Alzheimer's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-12-25
- Last Posted Date
- 2010-08-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 99
- Registration Number
- NCT01039701
- Locations
- 🇸🇰
Research Site, Zlate Moravce, Slovakia
Study to Evaluate Safety, Tolerability and Pharmacokinetics (PK) (Including Food Effect) of Oral Doses of AZD5847 in Healthy Volunteers
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2010-07-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT01037725
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
AZD5423 Multiple Ascending Dose Study
- First Posted Date
- 2009-12-23
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT01037504
- Locations
- 🇬🇧
Research Site, London Bridge, Greater London, United Kingdom
AZD9668 Relative Bioavailability
- First Posted Date
- 2009-12-18
- Last Posted Date
- 2013-01-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT01035411
- Locations
- 🇩🇪
Research Site, Berlin, Germany
AZD9668 Relative Bioavailability
- First Posted Date
- 2009-12-18
- Last Posted Date
- 2010-02-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT01034982
- Locations
- 🇩🇪
Research Site, Berlin, Germany
A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.
- First Posted Date
- 2009-12-15
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT01031836
- Locations
- 🇯🇵
Research Site, Shinjuku-ku, Japan
Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension
Phase 3
Completed
- Conditions
- Type 2 Diabetes MellitusInadequate Glycaemic ControlCardiovascular DiseaseHypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 922
- Registration Number
- NCT01031680
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Centralized Pan-Middle East Survey on the Under-treatment of Hypercholesterolemia, Sub-study for the Gulf States
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2011-05-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT01031277
- Locations
- 🇦🇪
Research Site, Abu Dhabi, United Arab Emirates
This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2012-07-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT01030224
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 912
- Registration Number
- NCT01029886
- Locations
- 🇨🇳
Research Site, Yung-Kang, Tainan, Taiwan
🇷🇴Research site, Oradea, Romania